Anna Dirner
Research Subjects
Anna Dirner has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Barbara Vodicska
Oncompass Medicine Hungary Kft, Budapest, Hungary
2 shared publications - Dora Lakatos
Oncompass Medicine Hungary Ltd., 1024 Budapest, Hungary
2 shared publications - Dóra Tihanyi
Genomate Health Inc, Cambridge, USA
2 shared publications Edit Várkondi
Oncompass Medicine Hungary Ltd, Budapest, Hungary
2 shared publications- István Peták
Oncompass Medicine Hungary Kft, Budapest, Hungary
2 shared publications Júlia Déri
Oncompass Medicine Hungary Ltd, Budapest, Hungary
2 shared publications
Latest Publications
- Open Access
- 30 May 2025
- Published by Springer Nature in npj Precision Oncology
- Vol. 9 (1) , 1-10
Real-world performance analysis of a universal computational reasoning model for precision oncology in lung cancer
Tumors harbor multiple genetic alterations, yet treatment decisions are commonly based on single biomarkers, leading to underutilization of genomic information by comprehensive molecular tests, uncertainty in clinical practice, and frequent treatment failures. Although molecular tumor boards can assist personalized treatments, this process is not scalable or standardized, resulting in highly discordant recommendations. Validated digital solutions for personalized decision support are highly needed. The Digital Drug Assignment (DDA) system is a computational reasoning model that scores treatment options based on the full tumor genomic data. We retrospectively analyzed data of 111 lung cancer patients and found that high-score MTAs (1000≦DDA score) provided significant clinical benefit over other treatments, in terms of ORR, PFS, and OS. These results demonstrate that the DDA system is predictive of relative benefit of the various agents used in lung cancer care. Digital drug assignment can potentially address challenges with complex molecular profiles in routine clinical settings.
- 30 May 2025
- Published by Springer Nature in npj Precision Oncology
- Vol. 9 (1) , 1-10
Open AccessReal-world performance analysis of a universal computational reasoning model for precision oncology in lung cancer
Tumors harbor multiple genetic alterations, yet treatment decisions are commonly based on single biomarkers, leading to underutilization of genomic information by comprehensive molecular tests, uncertainty in clinical practice, and frequent treatment failures. Although molecular tumor boards can assist personalized treatments, this process is not scalable or standardized, resulting in highly discordant recommendations. Validated digital solutions for personalized decision support are highly needed. The Digital Drug Assignment (DDA) system is a computational reasoning model that scores treatment options based on the full tumor genomic data. We retrospectively analyzed data of 111 lung cancer patients and found that high-score MTAs (1000≦DDA score) provided significant clinical benefit over other treatments, in terms of ORR, PFS, and OS. These results demonstrate that the DDA system is predictive of relative benefit of the various agents used in lung cancer care. Digital drug assignment can potentially address challenges with complex molecular profiles in routine clinical settings.